Innovation Sphere

Projects Sharing Researchers

Communicate

Details

Project TitleAnti-Cancer T Cells and their Preparation
Track Code16029
Short Description

A novel method to enhance efficacy of cell therapy modality involving T cell populations


 
Abstract

The role of each of the subtypes of T-cells in an immune response remains elusive. We have developed a novel method to modulate Tc22 lineage T cells from a population of CD8+ T cells that can impact the outcome of an immunotherapy treatment regimen. The method involves: a) providing a population of CD8+ T cells; b) activating the population of CD8+ T cells; and c) culturing or contacting the population of CD8+ T cells with a specific combination of cytokines and compounds. The aim of this innovation is to dramatically improve the efficacy of immuno-oncology programs involving T cell therapy.


 
 
Tagscancer, Immuno-oncology, cell therapy, regenerative medicine, stem cell, platform, Tumor Infiltrating Lymphocytes, ANTI-CANCER T CELLS AND THEIR PREPARATION
 
Posted DateJun 8, 2017 5:50 PM

Potential Applications

  • Cancer treatment
  • Regenerative medicine
  • Immunotherapy

Principal Investigator

Drs. Michael St. Paul, Sam Saibil, and Pamela Ohashi, University Health Network

Patent Status

Provisional application has been filed US62/447,491

Partnering Opportunity

Available for licensing

Publications

Nat Med. 2017 Mar;23 (3):368-375. A distinct innate lymphoid cell population regulates tumor-associated T cells

For Further Information, Please Contact:

Rahbar Rahimpour, PhD, MBA | Licensing and Commercialization Professional | Technology Development and Commercialization | University Health Network | +1 (416) 581-7728 | rahbar.rahimpour@uhnresearch.ca